Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

2020264 citationsJournal Article

Authors

Rohit Loomba · University of California San Diego

Mazen Noureddin · Cedars-Sinai Medical Center

Kris V. Kowdley · Liver Institute Northwest

Anita Kohli · Arizona Liver Health

Aasim Sheikh · GI Specialists of Georgia (United States)

Guy Neff · Covenant Research and Clinics (United States)

Bal Raj Bhandari

Abstract

In patients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was well tolerated, led to improvements in NASH activity, and may have an antifibrotic effect. This combination offers potential for fibrosis regression with longer-term therapy in patients with advanced fibrosis attributable to NASH.

Topics & Keywords

Liver Disease Diagnosis and Treatment Liver Diseases and Immunity Hepatitis C virus research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 73, Issue 2, pp. 625-643

DOI: 10.1002/hep.31622

Field-Weighted Citation Impact: 21.96